Vinpocetine
Generic medicine reference
Not yet clinically reviewed
This entry was migrated from the earlier Pharmapedia app bundle and has not been reviewed by a named clinician on this site. It is provided for educational reference only — verify dosage and safety information against current, authoritative sources and a qualified healthcare professional before any clinical use.
Overview
Vinpocetine exerts antioxidant effects. In animal models, vinpocetine inhibited the formation of reactive oxygen species and lipid peroxidation. Cai 2012 , Cai 2013 , Medina 2006 , Nivison-Smith 2014 , Sozański 2011 , Zaki 2013 , Zhuang 2013 Inhibition of calcium calmodulin-dependent phosphodiesterase type 1 has been demonstrated. Increases in cyclic adenosine 3′,5′-monophosphate (cAMP) may be responsible for benefits in cerebral circulation and decreased platelet aggregation. Additionally, the prevention of cAMP breakdown results in maintenance of the protein kinase and transcription factor cAMP-responsive, element-binding protein activation, possibly improving memory processing. Cai 2013 , Medina 2006 , Sozański 2011 Prevention of the upregulation of NF-kappaB and pro-inflammatory mediators by vinpocetine has been demonstrated. Medina 2010 , Zhuang 2013
Indications
Vinpocetine exerts antioxidant effects. In animal models, vinpocetine inhibited the formation of reactive oxygen species and lipid peroxidation. Cai 2012 , Cai 2013 , Medina 2006 , Nivison-Smith 2014 , Sozański 2011 , Zaki 2013 , Zhuang 2013 Inhibition of calcium calmodulin-dependent phosphodiesterase type 1 has been demonstrated. Increases in cyclic adenosine 3′,5′-monophosphate (cAMP) may be responsible for benefits in cerebral circulation and decreased platelet aggregation. Additionally, the prevention of cAMP breakdown results in maintenance of the protein kinase and transcription factor cAMP-responsive, element-binding protein activation, possibly improving memory processing. Cai 2013 , Medina 2006 , Sozański 2011 Prevention of the upregulation of NF-kappaB and pro-inflammatory mediators by vinpocetine has been demonstrated. Medina 2010 , Zhuang 2013
Contraindications
Hypersensitivity to Vinpocetine or any component of product, Pregnancy, Lactation, Patients under 18 year age.
Side Effects
The symptomatic adverse reactions produced by Vinpocetine are more or less tolerable and if they become severe, they can be treated symptomatically, these include Transient Tachycardia, Transient Hypotension, Immature beats, Pressure-type headache, Facial flushing, Nausea, Dizziness, Insomnia, Dry mouth.
Warnings
No data regarding the Warnings/Precautions of Vinpocetine is available.
High Risk Groups
Drug should not be given to Cardiac / Hypertensive Patients, and Pregnant Mothers. If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Adult Dosage
20 mg (20 (20)) 24 hourly Slow IV —
5 g (5 (5)) 24 hourly PO —
Child Dosage
No child dosage information is recorded for this medicine yet.
Neonatal Dosage
No neonatal dosage information is recorded for this medicine yet.
Drug Interactions
Caution is warranted in patients on anticoagulant medications.
Storage
No storage information is recorded for this medicine yet.
Available Brands in Pakistan
No active brands are currently recorded for this generic.
1 record is present but flagged "Unverified / Legacy" and excluded.